Lupin claims to have acquired the trademarks Ondero and Ondero Met from Boehringer Ingelheim

21 Aug 2023 , 10:11 AM

Lupin announced on Friday that it has purchased the trademark rights for the diabetes medications Ondero (linagliptin) and Ondero Met (linagliptin and metformin) from Boehringer Ingelheim for 26 million euros (Rs 235 crore) in an all-cash transaction.

Ondero and Ondero Met’s most recent sales were not disclosed by Lupin, however, the company did state that the acquisition was anticipated to add value to its range of diabetes medications.

As part of a co-marketing agreement with Boehringer Ingelheim India, Lupin has been promoting Ondero and Ondero Met in the Indian market since 2015.

As a global leader in the anti-diabetes market, Lupin further cemented its position with the acquisition of Ondero and Ondero Met, according to Nilesh Gupta, MD. ‘With the acquisition of Ondero and Ondero Met, we continue to offer a wide portfolio of products to enable access to medication for patients.’

For feedback and suggestions, write to us at [e-mail]